

**BOOK NOW AND
SAVE UP TO £400**

December 10-12, 2018 | London, UK

www.as-immunetolerance-eu.com



Antigen-Specific Immune Tolerance Europe

**Optimizing the Discovery, Translation and
Clinical Development of Safe and Effective
Antigen-Specific Immune Tolerance Inducing
Therapies to Treat Autoimmune Diseases**

Expert Speakers Including:



Robert (Bob) Anderson
CSO
ImmusanT



Arpita Maiti
Senior Director, External
Science & Innovation,
Inflammation, Immunology
and Microbiome
Pfizer



Keith Martin
CEO
Apitope



Timm Jessen
CEO
Topas Therapeutics



Lawrence Steinman
Professor at Stanford
University; Chairman of
the Board
Tolerion



David Wraith
Institute Director of
Immunology & Immunotherapy
and Professor of Immunology
University of Birmingham



Tim Schmidt
VP Chief Translational
Research Officer
TxCell



José Carballido
Executive Director of
Institutes Biomedical
Research
Novartis



Mark Peakman
Professor of Clinical
Immunology- Faculty of
Life Sciences & Medicine
King's College London

Partners:



TxCell

Topas



Therapeutics

Antigen-Specific Immune Tolerance Europe 2018

Successfully Overcome the Discovery, Translation and Product Development Challenges Associated with Developing Safe and Effective Antigen-Specific Immune Tolerance Therapies for Autoimmune Disorders.

As the first generation of antigen-specific immune tolerance therapies enter the clinic and excitement around recent partnerships, IPOs and investments reaches new heights, now is the time for an industry forum for large pharma, pioneering biotech and academia to unite.

Tackling key R&D challenges, such as **antigen identification**, **animal model predictability**, **translation** and **clinical design**, this meeting is the first European centric, dedicated platform that brings key decision makers together to drive the future success of these novel therapies.

With excitement and opportunity for those who act now to successfully identify robust predictive models and translate basic immune tolerance research into effective therapies for autoimmune diseases, join the **1st Antigen-Specific Immune Tolerance Europe 2018** to rapidly translate the hype into a drug development reality.

Why our speakers are looking forward to this summit?

■ To attend a meeting that brings together key experts in all therapeutic modalities for immune tolerance induction, including Tregs, antigen-specific immune tolerance, and potentially CARTregs ■■

Arpita Maiti, Pfizer

■ We had a good meeting in Boston in April, and I'm looking forward to sharing with colleagues across the Atlantic ■■

Lawrence Steinman, Tolerion

■ Meeting experts of the immune tolerance field and exchange on our activities ■■

Nicolas Poirier, OSE Immunotherapeutics

Why Attend the 1st Antigen-Specific Immune Tolerance Europe 2018?

1.

Revisit and widen your understanding of the emerging field of antigen-specific immune tolerance therapies with insights from **Pfizer, Novartis & University College London**



2.

Explore the function of Tregs in autoimmunity & achieving antigen-specific immune tolerance with insights from **University of Birmingham, TxCell & OSE Immunotherapeutics**



3.

Analyze the latest pre-clinical strategies to induce antigen-specific immune tolerance with insights from **Allero Therapeutics, Toleranzia AB & Anokion/Kanyos Bio**



4.

Maximize your success rates by improving the pre-clinical predictability of antigen-specific immune tolerance therapies with insights from **Topas Therapeutics, Newcastle University & NIH**



5.

Strategize and optimize clinical trial designs and product development with insights from latest clinical trials of **Apitope, ImmusanT, ActoBio Therapeutics & Selecta Biosciences**



Your Expert Speakers



Robert (Bob) Anderson
CSO
ImmunanT



Arpita Maiti
Senior Director, External
Science & Innovation,
Inflammation,
Immunology and
Microbiome
Pfizer



Keith Martin
CEO
Apitope



Timm Jessen
CEO
Topas Therapeutics



Pierre Vandepapeliere
CEO & CMO
ImCyse




Charlotte Friert
CEO
Toleranzi AB



Mark Peakman
Professor of Clinical
Immunology- Faculty
of Life Sciences &
Medicine
King's College London



Lawrence Steinman
Professor at Stanford
University; Chairman of
the Board
Tolerion



Ethan Shevach
Senior Investigator-
Laboratory of Immune
System Biology
NIAID/NIH



David Wraith
Institute Director
of Immunology &
Immunotherapy and
Professor of Immunology
**University of
Birmingham**



Tim Schmidt
VP Chief Translational
Research Officer
TxCell



Poul Sørensen
CSO
Allero Therapeutics



José Carballido
Executive Director of
Institutes Biomedical
Research
Novartis



John Isaacs
Professor of Clinical
Rheumatology
Newcastle University



Kei Kishimoto
CSO
**Selecta Biosciences
Inc.**



Pieter Rottiers
CEO
ActoBio Therapeutics



Stephan Kontos
Co-Founder & CSO
**Anokion and Kanyos
Bio**



Nicolas Poirier
CSO
**OSE
Immunotherapeutics**



Céline Dumont
Senior Director
Preclinical
Pharmacology and
Safety
TxCell



Catharien Hilken
Reader in
Immunotherapy
Newcastle University



David Klatzmann
Director - Clinical
Investigation Center for
Biotherapy
**Sorbonne University
& Pitié-Salpêtrière
Hospital**



Michael Boyne
VP of Product
Development and
Analytics
Cour Pharmaceuticals

WHY ARE OUR EXPERT SPEAKERS GETTING INVOLVED AT THE SUMMIT?

There is a considerable momentum in academia, biotech and large pharma to develop novel therapeutics capable of inducing immune tolerance. Events like this one offer a tremendous opportunity to learn from each other and eventually join forces to close the huge medical gap we have in autoimmunity and other related diseases



José Carballido
Novartis

To participate in cutting edge discussions about one of the major challenges in modern medicine, antigen specific immune tolerance



Mark Peakman
King's College London

To present our platform and its applications in the autoimmunity space, and to network with colleagues with interest in the same space



Pieter Rottiers
ActoBio Therapeutics

I look forward to translational insights from leaders in the field of antigen-specific immunotherapy



Robert (Bob) Anderson
ImmusanT

Learning and exchanging views on the innovative and new research ongoing to restore immune tolerance presented by experts in the field



Céline Dumont
TxCell

I look forward to further exchanges with specialists in the field of Antigen-Specific Immune Tolerance, to deepen and broaden dialog started at the first Antigen-Specific Immune Tolerance Summit in Boston, which was quite illuminating



Charlotte Fribert
Toleranzi AB

Antigen-specific immunotherapy is considered the 'holy-grail' for treatment of autoimmune diseases. This summit will reveal how effective antigen-specific immunotherapy is being realised through clinical trials in patients



David Wraith
University of Birmingham

To network with peers in this rapidly developing field and discuss the latest findings and developments with them



Poul Sørensen
Allero Therapeutics

Conference Day One | Tuesday, 11th December, 2018

8.00 Registration & Breakfast

8.50 Chair's Opening Remarks



Arpita Maiti

Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome
Pfizer

Harnessing Tregs to Induce Antigen-Specific Immune Tolerance

David Wraith

Institute Director
of Immunology &
Immunotherapy
and Professor of
Immunology
University of
Birmingham

9.00 Antigen-Specific Immunotherapy of Autoimmune Diseases

- Different approaches to antigen-specific immunotherapy with autoantigens have been designed
- These generate immune suppression of disease through induction of distinct populations of regulatory T cells
- Antigen-specific immunotherapy with soluble peptides has proven well tolerated with evidence of efficacy in different autoimmune conditions

Céline Dumont

Senior Director
Preclinical
Pharmacology and
safety
TxCell

9.30 Innovation in Restoring Immune Tolerance in Autoinflammatory Disease: Engineering CAR Regulatory T Cells

- Engineering CAR regulatory T cells as an alternative to antigen specific Tregs
- CAR Tregs as a new modality to restore immune tolerance
- Harnessing new potential activity of Tregs beyond their suppressive function to bring new medicine to patients

José Carballido

Executive Director of
Institutes Biomedical
Research
Novartis

10.00 Leveraging Antigen-Specific Regulatory T Cell Responses to Defeat Type 1 Diabetes

- Induction of autoantigen-specific regulatory T cells is a very promising mechanism to dampen polyclonal autoreactivity without impairing broad immune function
- One single antigen specificity is required and sufficient to restore immune homeostasis
- Precision, and not personalized, immunotherapy has the potential to solve the medical need in T1D

David Klatzmann

Director - Clinical
Investigation Center
for Biotherapy
Sorbonne University
& Pitié-Salpêtrière
Hospital

10.30 On Treg, IL-2 and Tolerance

- Understanding Treg specificity is key to understanding (antigen specific) tolerance
- Low dose IL-2 stimulates and expands Tregs
- Combined use of IL-2 and antigen could be an ultimate way to establish antigen specific tolerance

11.00 Speed Networking & Morning Refreshments

Validation of Antigen-Specific Targets: Benchmark Against the Latest Scope & Strategies

Arpita Maiti

Senior Director,
External Science
& Innovation,
Inflammation,
Immunology and
Microbiome
Pfizer

12.00 Accessing Innovation in Antigen-Specific Immune Tolerance - A Big Pharma View

- Antigen-specific immune tolerance will form the basis of future transformative therapies for autoimmune diseases that have the potential to be curative
- Approaches/modalities to induce immune tolerance are complex and will require innovation across the drug development and commercialization pathway
- Big pharma deploys multiple vehicles to access this innovation and augmenting it with in-house capabilities to bring new medicines to patients in need

Poul Sørensen

CSO
Allero Therapeutics

12.30 Translating the Learnings from Allergen Immunotherapy for Inducing Long Term Antigen-Specific Tolerance

- How to develop novel targeted treatments that induce antigen-specific tolerance with a long lasting effect in immune mediated disorders?
- How to identify and validate disease-specific antigen targets, biomarkers and route of administration to translate these learnings into effective autoimmunity therapies for patients with immune mediated disorders?
- Update on Allero Therapeutics efforts for demonstrating proof-of-principle in immune mediated disorders

 Mark Peakman Professor of Clinical Immunology- Faculty of Life Sciences & Medicine King's College London	13.00 Measuring and Limiting Antigen-Specific Immune Tolerance in Type 1 Diabetes • Systematic approaches to epitope discovery • Highly sensitive diagnostic toolkits • Strategies for inducing immune tolerance
--	--

13.30 Networking Lunch

**Advancing Pre-Clinical Development of
Novel Antigen-Specific Immune Tolerance Therapies**

 Charlotte Fribert CEO Toleranzi AB	14.30 TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis • TOL2 treatment modalities • Tolerance induction and maintenance using TOL2 • Preclinical development of TOL2
--	---

 Nicolas Poirier CSO OSE Immuno-therapeutics	15.00 Anti-IL7Ra Antibody: Next Generation Anti-Cytokine Therapy • OSE immunotherapeutics is developing novel immunotherapies targeting activation and regulation pathways of the immune system • Anti-IL7Ra mAb targets the fuel of effector and memory T lymphocytes while sparing regulatory T cells • Appropriate anti-IL7Ra mAb induce long-term and robust antigen-specific immune tolerance in non-human primate by clonal deletion of experienced anti-gen-specific memory T cells
---	--

 Stephan Kontos Co-Founder & CSO Anokion and Kanyos Bio	15.30 Targeted Antigen Delivery to the Liver Via Synthetic Glycosylation Induces Robust Antigen-Specific Tolerance • Active targeting domains deliver antigen to tolerogenic pathways in the liver, and induce robust antigen-specific tolerance in both mouse and non-human primate models of immunity • Our technologies are translational, in that the mechanisms induced are consistent with unmet clinical needs, and our molecules are developable • Discuss potential approaches to de-risk MoA's in higher-order species, and consider their value
---	--

16.00 Afternoon Refreshments & Networking

16.30 Roundtable Discussions:

Our breakout roundtables will allow you to have more intimate discussions with thought leaders of the field of autoimmunity around some of the hottest topics in the field. Discover multiple perspectives on these key issues, so that you can learn from your fellow experts in the audience. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:

1.

What is antigen-specific immune tolerance and do we know how to effectively measure it?

2.

How to identify and validate the right antigen(s) to be targeted in complex autoimmune diseases?

3.

What are the challenges and opportunities in developing durable antigen-specific immune tolerance both mechanistically and clinically?

17.00 Chair's Closing Remarks & End of Day One

Conference Day Two | Wednesday, 12th December, 2018

8.30 Breakfast & Networking

8.55 Chair's Opening Remarks



Arpita Maiti

Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome
Pfizer

Overcoming Translational Challenges of Antigen-Specific Immune Tolerance Therapies into the Clinic



Tim Schmidt

VP Chief Translational
Research Officer
TxCel

9.00 Next Generation Immuno-Therapy for Transplant Rejection and Auto-Immunity: The CAR Treg Foray into The Clinic

- CAR Tregs as potential avenue to tolerance induction
- TxCell's CAR Treg technology and lessons learned in preparation of the first-in-patient trial
- Design of TxCell's Ph1/2a HLA-A2 CAR Treg trial in renal transplant patients



Timm Jessen

CEO
Topas Therapeutics

9.30 Liver Based Immune Tolerance Induction

- Harnessing the natural immune tolerance capabilities of the liver
- Nanoparticles as mimics of blood borne antigens
- Product development aspects in nanomedicine



John Isaacs

Professor of Clinical
Rheumatology
Newcastle University

10.00 Industry-Academia Collaborations to Identify Novel Biomarkers

- Industry-academia collaborations in the pre-competitive space provide critical synergies for biomarker development
- The MRC/ABPI RA-MAP consortium focussed on biomarker discovery in rheumatoid arthritis
- The outputs have enhanced our knowledge of RA, including the identification of distinct endotypes

10.30 Panel Discussion: Improving Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies

- How to develop robust potency assays and validate them for autoimmunity antigen-specific therapies?
- What are the criticism on the meaning of various pre-clinical data showing antigen-specific immune tolerance induction?
- How to overcome the lack of standardization of result across the industry and increase the reproducibility of pre-clinical data?

Panel Moderator:



Keith Martin

CEO
Apitope

Panelists:



Timm Jessen

CEO
Topas Therapeutics



John Isaacs

Professor of Clinical
Rheumatology
Newcastle University



Pieter Rottiers

CEO
ActoBio Therapeutics

11.00 Morning Refreshments & Networking

Optimizing Clinical Development & Paving the Future of Antigen-Specific Immune Tolerance Therapies



Keith Martin

CEO
Apitope

11.30 Antigen Specific Immunotherapy with Apitopes®: From Concept to Clinic

- Design of Apitopes® to induce antigen specific tolerance
- Pre-clinical validation of Apitope® peptide therapy for inducing tolerance and disease modification
- Safety and efficacy Apitopes® in early clinical trials

 Robert (Bob) Anderson CSO ImmusanT	12.00 Clinical and Immunological Effects of Peptide-Based Epitope-Specific Immunotherapy (ESIT) In Celiac Disease • Gluten food challenge enables epitope and biomarker discovery studies in patients as well as clinical development of antigen-specific immunotherapy in celiac disease • In patients with celiac disease, peptide selection based on consistency of epitope hierarchy ex vivo translates to consistency of immune responsiveness to ESIT • Dose optimization to achieve immune unresponsiveness to high levels of antigenic peptides can be guided by clinical effects and immune biomarkers
 Lawrence Steinman Professor at Stanford University; Chairman of the Board Tolerion	12.30 Engineered DNA Plasmid for Tolerance in Type 1 Diabetes, NMO and Gene Therapy • Results of Phase 2 trial in type 1 diabetes demonstrating increase in C-peptide • Use of high tech to demonstrate antigen specific tolerance • Platform opportunities in gene therapy and other autoimmune disease
 Kei Kishimoto CSO Selecta Biosciences Inc.	13.00 Pre-Clinical and Clinical Development of ImmTOR Technology • ImmTOR technology is comprised of tolerogenic nanoparticles carrying rapamycin which confers immune to tolerance to co-administered antigens • We have initially applied the technology to mitigate the formation of anti-drug antibodies to biologic drugs. We will present case examples from our ongoing clinical trials • Application to autoimmune diseases will also be discussed

13.30 Networking Lunch

Demonstrating Clinical Efficacy: Tackling Autoimmune Diseases Through Antigen-Specific Immune Tolerance Therapies

 Pieter Rottiers CEO ActoBio Therapeutics	14.30 Actobiotics® - A New Class of Microbe-Based Biopharmaceuticals • Update on oral Lactococcus lactis-based protein delivery platform • How to encourage disease specific immune tolerance induction? • ActoBio's approach to tackle Type 1 Diabetes
 Pierre Vandepapeliere CEO & CMO ImCyse	15.00 Imotopes Induce Cytolytic CD4 T Cells as a Novel Strategy to Treat Autoimmune Diseases • Ulmotopes induce cytolytic CD4 T cells that will induce specifically apoptosis of APCs and effector T cells involved in auto immune disease processes • Different mechanism of action as compared to all T Reg inducing strategies • PoC has been demonstrated ins several disease models and is now in clinics
 Michael Boyne VP of Product Development and Analytics Cour Pharmaceuticals	15.30 Bringing Antigen-Specific Therapies to the Clinic • Inducing tolerance without immune suppression by harnessing nanoparticle technology • Immune intervention in celiac disease: a case study • Beyond discovery and mechanism – bringing novel immune therapies to humans
	16.00 Chair's Closing Remarks & End of Antigen-Specific Immune Tolerance Summit Europe

Pre-Conference Workshop Day | Monday, 10th December, 2018

Workshop A

Translation from Animal to Human Studies: Role of T Regulatory Cells in the Induction/Maintenance of Tolerance

10.00am - 12.30pm

T regulatory cells expressing the transcription factor Foxp3 are critical for the maintenance of immune homeostasis. Enhancement of Treg function or numbers hold great promise for the treatment of both organ-specific and systemic autoimmune diseases. This workshop will deal with multiple approaches to accomplish those goals. As antigen-specific Treg cells have been shown to be most potent suppressors of autoimmune disease in animal models, a major focus of the discussion will be the generation and therapeutic use of antigen-specific Treg cell therapy in man.

Through attending this unique workshop, you will discover & assess the following:

- Will induction of tolerance with Tregs be permanent or long-lasting?

- Hear about and discuss the mechanisms of action of Foxp3+ Treg cells
- Can Treg function be enhanced in vivo with IL-2?
- Hear about and discuss antigen-specific versus polyclonal Treg cells approaches?
- Hear about and discuss cellular biotherapy with Tregs to induce tolerance
- Hear about and discuss optimal methods for the induction/expansion of antigen-specific Tregs
- Hear about and discuss if antigen-specific tolerance be induced with Foxp3- T cells



Workshop Leader

Ethan Shevach

Senior Investigator- Laboratory of Immune System Biology
NIAID/NIH

Workshop B

Standardization Considerations for Therapeutic Antigen-Specific Tolerogenic Strategies

13:30pm - 16.00pm

First generation of antigen-specific immune tolerance therapies in clinic have shown promising outlooks for the future of this emerging and exciting field, however, it is still unclear whether these treatments have any lasting, beneficial clinical effects. Major outstanding questions that need addressing include the antigen-specificity of these therapeutic approaches, the location where they act, the optimal route of administration, and how to determine their effectiveness in vivo. In addition, as these clinical trials have been at small scale, and the approach taken by these trials varied considerably, the outcomes of these trials could not easily be compared. Standardization/harmonization of defined aspects of future clinical trials is needed to enable useful comparisons between different trials.

Through attending this unique workshop, you will discover & assess the following:

- Considering the optimal administration route
- Hear about and discuss biomarkers of tolerance
- Hear about and discuss how to standardize/harmonize immune monitoring?
- Hear about and discuss the benefits of reporting standards
- Hear about and discuss the way forward to standardize different classes of therapeutics approaches to achieve antigen-specific immune tolerance with reference to tolerogenic cell therapies as case study



Workshop Leader

Catharien Hilkens

Reader in Immunotherapy
Newcastle University

BECOME A COMMERCIAL PARTNER



Industry Partner

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting transplantation as well as a range of autoimmune diseases (both T-cell and B-cell-mediated), such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases or inflammatory skin diseases. TxCell's cellular immunotherapies are based on regulatory T lymphocytes (Tregs). Tregs are a T cell population discovered in the nineties for which anti-inflammatory properties have been demonstrated. Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing engineered antigen-specific Tregs, where the antigen specificity is brought by a Chimeric Antigen Receptor (CAR) (CAR-Treg cells).

www.txcell.com



Industry Partner

Topas Therapeutics (Hamburg, Germany) is focused on developing products in areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas' technology induces antigen-specific regulatory T cells in the liver by mimicking bloodborne antigens via the Company's proprietary peptide-loaded nanoparticles. Topas has programs in MS, T1D and an orphan indication, which is planned to enter the clinic in 2019. The Company has collaborations with Eli Lilly and Company and with Evotec.

www.topas-therapeutics.com

WHY SPONSOR?

- Benefit from Market Intelligence**
There is a severe unmet medical need as it currently stands to battle autoimmunity. Hear how and where pharmaceutical giants are looking to close this gap to match your solutions accordingly
- Raise Brand Awareness**
Benefit from pre and post conference exposure to our autoimmunity community and increase market share through unique branding formats. Also, differentiate your autoimmune target discovery and pre-clinical services from other solution providers
- Position Yourself as an Industry Expert**
With the emergence of first generation of clinical data, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent clinical expertise in front of the key decision makers in the field
- Meet and Network with Industry Pioneers**
With a room full of drug developers looking to see how they can effectively apply targeted immune tolerance solutions to increase clinical success, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions
- Generate Commercial Collaborations**
Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event

WHO WILL YOU MEET?



60+ Attendees



6+ Hours of Dedicated Networking



2 Interactive Workshops



20+ Real World Case Studies

BECOME A PARTNER



Nathan Wilgoss

Partnerships Manager- Antigen-Specific Immune Tolerance Series

T: +44 (0) 20 3141 8739

E: nathan.wilgoss@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

Tel: +44 (0)20 3141 8700

Email: register@hansonwade.com

Web: www.as-immunetolerance-eu.com/take-part/register

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Contact: register@hansonwade.com

1

Find out about the most innovative therapeutic approaches that target immune tolerance pathways

2

Debate, challenge and cut through the hurdles associated with successful translation from pre-clinical to clinical development and how to design robust human trials for effective antigen-specific immune tolerance therapies

3

Find out what is the future direction of the field of antigen-specific immune tolerance therapies from the key decision makers within the biopharmaceutical industry

SECURE YOUR PLACE

Drug Developers (Pharma & Biotech)	SAVE £400 Register & Pay before 05 October 2018*	Standard Prices*
Conference + 2 Workshops	£2497	£2897
Conference + 1 Workshop	£2098	£2498
Conference Only	£1599	£1999
Workshop Only	£499	

Academic & Not-For-Profit	SAVE £200 Register & Pay before 05 October 2018*	Standard Prices*
Conference + 2 Workshops	£1538	£1738
Conference + 1 Workshop	£1299	£1499
Conference Only	£999	£1199
Workshop Only	£299	

*all prices subject to 20% VAT



VENUE

Park Plaza Victoria

239 Vauxhall Bridge Road, London
SW1V 1EQ, United Kingdom

For further information or assistance, please visit
www.parkplaza.com/london-hotel-gb-sw1v-1eq/gbvictor

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 8149